Solu

What Solu does

Solu, founded in 2022 and headquartered in Helsinki, Finland, and operating as Solu Healthcare, Inc. in the United States, has built a cloud-based genomic surveillance platform that automates the analysis of microbial genomes without requiring code, command-line tools, or local configuration. The platform accepts sequencing data via a browser interface and runs end-to-end bioinformatics workflows including read quality verification, de novo genome assembly for short and long reads, antimicrobial resistance (AMR) gene and point mutation annotation, whole-genome SNP variant calling, virulence factor detection, maximum-likelihood phylogenetic tree construction, plasmid-borne AMR detection, and core genome Multilocus Sequence Typing (cgMLST) built on community-standard schemes validated against published studies. The product targets hospital laboratories, infection prevention and control (IPC) teams, and academic and government research institutions that need to identify antibiotic-resistant bacteria and respond to outbreaks faster than conventional bioinformatics pipelines allow, with stated outcomes of reducing bacteria identification time from hours to minutes.

The company monetizes the platform through a SaaS subscription model with a self-serve 14-day free trial and free account creation, complemented by quote-based enterprise contracts for larger deployments. Go-to-market combines product-led growth through the platform.solugenomics.com signup flow with enterprise field sales targeting hospitals, public-health agencies, and university research groups. Named users and collaborators include Cedars-Sinai Medical Center, ESR and Awanui Labs in New Zealand, Stanford University, the University of Hamburg, UZ Leuven, the NIH, Institut Pasteur, the University of Oxford, and UAE University. The platform holds ISO 27001 certification and GDPR compliance attestation, supporting procurement in regulated European and healthcare environments. Solu raised €1 million in seed funding in June 2023 from Lifeline Ventures (lead) and Wave Ventures to develop its pathogen DNA library and expand operations, and as of mid-2024 had fewer than ten employees with no disclosed revenue.

Name

Solu

Legal name

Solu Healthcare, Inc.

Website

https://solu.bio

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Solu provides a cloud-based genomic surveillance platform that automates microbial genome analysis and antimicrobial resistance detection without code, serving hospital laboratories, infection prevention teams, and academic and government research institutions globally.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Software Publishers (513210), Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Microbiology LIS/LIMS (HLACAMAD), Laboratory-Based Surveillance & Genomic Epidemiology (WGS/NGS) (HLAJABAC)

Keywords

• Genomic surveillance software
• Microbial genome analysis
• Bioinformatics platform
• Antibiotic resistance detection
• Outbreak surveillance tools

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. SaaS Platform Subscription: Cloud-based genomic surveillance platform accessible via subscription. Users can sign up for free with a 14-day free trial, suggesting a freemium or subscription model with tiered pricing based on usage or features.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Solu operates a cloud-based, browser-accessible genomic surveillance platform that automates bioinformatics workflows for analyzing microbial genomes in real time. The platform performs read quality verification, de novo genome assembly, AMR gene annotation, variant calling, virulence detection, phylogenetic tree construction, plasmid analysis, and cgMLST comparison without requiring code or configuration. It is targeted at hospital laboratories, infection prevention and control teams, and research institutions for rapid identification of antibiotic-resistant bacteria and outbreak surveillance.

Product overview

Solu offers a unified genomic surveillance platform centered on the Solu Platform, a cloud-based web application that enables real-time analysis of microbial genomes without requiring coding or configuration. The platform integrates multiple bioinformatics modules including read quality verification, genome assembly, AMR gene annotation, variant calling, virulence detection, phylogenetic tree construction, plasmid analysis, and real-time collaboration. An additional capability is cgMLST (core genome Multilocus Sequence Typing), which provides a standardized method for comparing samples across institutions. The platform is designed for hospital laboratories, infection prevention teams, and research institutions to rapidly respond to potential outbreaks.

Differentiator

Problem solved

Functional benefit

Products and services

• Solu Platform Real-time genomic surveillance platform that enables analysis of microbial genomes directly in a web browser without requiring code or configuration. The cloud-based platform automates bioinformatics workflows including read quality verification, genome assembly, AMR gene annotation, variant calling, phylogenetic tree construction, and plasmid analysis. Designed for hospital laboratories, IPC teams, and research institutions to rapidly respond to potential outbreaks and identify antibiotic-resistant bacteria.

Quantifiable outcome

• Bacteria identification time reduced from hours to minutes
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Two partnerships are on record, tiered core.

• Stanford UniversitycoreStrategic or Co-development Partner · 15 June 2023Collaborative research partnership on antibiotic resistance. Stanford Professor Dr. Paul Bollyky has provided testimonials about the platform being intuitive and easy to use. The collaboration focuses on monitoring bacterial pathogen evolution and improving detection of superbugs for diagnostics and antibiotic development.
• University of HamburgcoreStrategic or Co-development Partner · 15 June 2023International university collaboration on antibiotic resistance research. Partner in the development of the pathogen DNA library for rapid identification of antibiotic-resistant bacteria.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Qiagen Digital Insights (CLC bio): Qiagen's bioinformatics division (formerly CLC bio) provides established genomic analysis workbenches widely used in clinical microbiology and infectious-disease research. It competes with Solu in the same hospital-lab and reference-lab customer base, but is bundled with Qiagen's broader sample-prep and assay portfolio rather than focused on AMR-specific surveillance.
• Benchling: Benchling is a cloud life-sciences R&D platform with expanding capabilities in molecular biology and sequence analysis used by biotech and academic customers. It overlaps with Solu on cloud-native lab workflows for researchers but is broader in scope, covering ELN, registry, and assay design rather than specializing in microbial genomic surveillance.
• Illumina BaseSpace Sequence Hub: Illumina BaseSpace is a cloud ecosystem for NGS analysis tightly integrated with Illumina sequencers and DRAGEN pipelines. It competes with Solu for the same sequencing-lab customer base, especially in clinical microbiology, and benefits from default placement on Illumina instruments that Solu must displace.

Direct peers

• DNAnexus: DNAnexus is a cloud-based bioinformatics platform serving clinical and translational genomics customers with automated pipelines for variant calling, assembly, and surveillance. Like Solu, it targets regulated healthcare and research institutions, offers a SaaS delivery model, and competes for AMR and infectious-disease genomic surveillance workloads.
• Geneious (Biomatters): Geneious is a desktop-and-cloud molecular biology toolkit used by microbiology labs for sequence alignment, assembly, and phylogenetic analysis. It addresses the same hospital-lab and academic researcher customers as Solu, with overlapping features (assembly, variant calling, trees) but a more generalist, code-friendly interface.
• BioNumerics (Applied Maths): BioNumerics is a specialized database and analysis platform for clinical microbiology and public-health typing, including cgMLST/wgMLST schemes and outbreak surveillance. It is one of Solu's closest direct competitors, serving public-health labs and reference laboratories with comparable AMR and outbreak-detection workflows.

Emerging players

• Chan Zuckerberg ID (CZID): CZID is a free, cloud-based metagenomic and pathogen genomic surveillance platform built with CZI funding. It overlaps with Solu on infectious-disease genomic analysis for research and public-health users, and competes on price (free) for academic and government segments where Solu's freemium tier also targets customers.
• Nextstrain: Nextstrain is an open-source pathogen-phylogenomics platform providing real-time tracking of viral and bacterial evolution. It shares Solu's surveillance and phylogenetic-tree functionality for outbreak response but is free, academic, and requires bioinformatics expertise, positioning it as an indirect competitor especially in research settings.
• PathogenWatch: PathogenWatch is a genomic surveillance platform for bacterial typing and AMR prediction developed by the Centre for Genomic Pathogen Surveillance. It targets the same public-health and reference-laboratory use cases as Solu (AMR gene detection, outbreak tracking) and represents a focused emerging competitor with academic backing.
• BugSeq: BugSeq is a no-code, cloud-based metagenomic and pathogen detection platform aimed at clinical microbiology labs. It is one of Solu's closest emerging competitors, offering a similar drag-and-drop, browser-based experience for users without bioinformatics expertise in hospital settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/solu-bio
• Xx.com/solu_bio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solu